Anti-psychotics are agents or medications used to treat the symptoms of schizophrenia and other psychotic disorders such as bipolar disorder and depression.
There is mounting evidence that CBD can reduce the symptoms of psychosis by impacting the dopamine system unlike existing anti-psychotics. CBD works partly by modulating the endocannabinoid system which plays a role in the modulation of neurotransmitters, metabolism and inflammation.
CBD is one of the main pharmacologically active phytocannabinoids.
It is non-psychoactive, but has many beneficial pharmacological effects, including anti-inflammatory and antioxidant effects. In addition, it belongs to a group of compounds with anxiolytic, antidepressant, antipsychotic, and anticonvulsant properties, among others. The biological effects of cannabidiol, including the various molecular targets, such as cannabinoid receptors and other components of the endocannabinoid system, with which it interacts, have been extensively studied. The therapeutic potential of CBD has been evaluated in cardiovascular, neurodegenerative, cancer, and metabolic diseases, which are usually accompanied by oxidative stress and inflammation.